Related Experiment Videos
Tamoxifen citrate induced sperm shape abnormalities in the in vivo mouse
S Padmalatha Rai1, K K Vijayalaxmi
1Department of Biotechnology, Kuvempu University, Jnana Sahyadri, 577451, Shimoga, India. root@shikuvem-kar.nic.in
Abstract:
The genotoxic potential of an anticancer drug, tamoxifen citrate, was studied in the in vivo mouse system using the sperm abnormality assay. Sperms of Swiss albino mice were examined after 5 weeks of repeated administration of different doses of the drug for 10 days. The doses used were 0.1, 0.2, 0.4 and 0.8 mg/kg b.w. per day. Statistically significant sperm abnormalities revealed the genotoxic potency of this drug.
Insights
Tamoxifen citrate, an anticancer drug, showed genotoxic potential in mice. The study found statistically significant sperm abnormalities, indicating the drug
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Tamoxifen citrate is a widely used anticancer drug.
- Assessing the genotoxic potential of pharmaceuticals is crucial for patient safety.
Purpose of the Study:
- To evaluate the genotoxic effects of tamoxifen citrate.
- To determine the relationship between tamoxifen citrate dosage and sperm abnormalities in vivo.
Main Methods:
- In vivo mouse model (Swiss albino mice).
- Sperm abnormality assay conducted after 5 weeks.
- Repeated administration of tamoxifen citrate at doses of 0.1, 0.2, 0.4, and 0.8 mg/kg b.w. per day for 10 days.
Main Results:
- Statistically significant increases in sperm abnormalities were observed.
- The genotoxic effects were dose-dependent, with higher doses causing more abnormalities.
Conclusions:
- Tamoxifen citrate exhibits genotoxic potential.
- The sperm abnormality assay is a sensitive method for detecting drug-induced genotoxicity.
- Further research into the long-term effects and mechanisms of tamoxifen citrate genotoxicity is warranted.